Atrium Biotechnologies Inc. announced today the closing of the acquisition of all MultiChem assets. This acquisition was financed through Atrium’s working capital, as well as from a new banking credit facility. MultiChem is a privately-held Canadian company specialized in the marketing of active ingredients and specialty chemicals.

“The MultiChem acquisition allows us to significantly increase our presence on the North American market in the active ingredients and specialty chemicals sector”, said Luc Dupont, President and Chief Executive Officer of Atrium. “Furthermore, it is part of our growth strategy aimed at positioning Atrium among the leaders at the international level, in both our activity sectors which are Active Ingredients & Specialty Chemicals, as well as Health & Nutrition.”

About Atrium Biotechnologies

Atrium Biotechnologies Inc. is an international company that develops, manufactures and markets value-added products and solutions for the cosmetics, pharmaceutical, chemical and nutritional industries. Atrium focuses mainly on growing segments of the health and personal care markets which are benefiting from the trends toward healthy living and the ageing of the population.